Fundz

Lilly to acquire Calytrix Bio for $1.5B

PUBLIC · LLYNov 16, 2026

Acquiring Company

Eli Lilly and Company

Acquired Company

Calytrix Bio

IndianapolisMassachusettsManufacturingBiotechnologyHealth CareMedicalPharmaceuticalBiotechnology

Description

Eli Lilly agreed on Monday to buy Calytrix Bio, a Wellesley, Massachusetts biotech developing treatments for myeloproliferative neoplasms, for up to $1.5 billion. The deal includes an upfront payment plus payouts tied to undisclosed clinical and regulatory milestones. Calytrix's CALR-targeting biparatopic antibody is the key asset Lilly is acquiring. The purchase adds to Lilly's streak of more than 15 acquisitions this year.

Other recent acquisitions in Medical and Pharmaceutical

Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.

Who to call at Eli Lilly and Company, and when

When Eli Lilly and Company changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Eli Lilly and Company raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Eli Lilly and Company, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Eli Lilly and Company. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Eli Lilly and Company

Location

Indianapolis, Indiana, United States

About

Lilly is a medicine company turning science into healing to make life better for people around the world. They have been pioneering life-changing discoveries for nearly 150 years, and today their medicines help more than 51 million people across the globe. Lilly is focused on redefining diabetes care, treating obesity, advancing the fight against Alzheimer's disease, providing solutions to immune system disorders, and transforming difficult-to-treat cancers into manageable diseases. To learn more, visit Lilly.com and Lilly.com/news, or follow them on Facebook, Instagram and LinkedIn.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Eli Lilly and Company makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Juan
Likely contact at this company
••••••••@••••••••

See Juan's verified email →

Miranda
Likely contact at this company
••••••••@••••••••

See Miranda's verified email →

Kay
Likely contact at this company
••••••••@••••••••

See Kay's verified email →

Suresh
Senior decision-maker at this company
••••••••@••••••••

See Suresh's verified email →

Shafaat
Senior decision-maker at this company
••••••••@••••••••

See Shafaat's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Eli Lilly and Company's next move

Learn about Strategic plan

Frequently asked

Who acquired Calytrix Bio?

Calytrix Bio was acquired by Eli Lilly and Company, based in Indianapolis. The deal was reported on November 16, 2026. Lilly is a medicine company turning science into healing to make life better for people around the world. Eli Lilly and Company is publicly traded (LLY) and operates in Manufacturing.

When did Eli Lilly and Company acquire Calytrix Bio?

Eli Lilly and Company's acquisition of Calytrix Bio was reported on November 16, 2026. Eli Lilly agreed on Monday to buy Calytrix Bio, a Wellesley, Massachusetts biotech developing treatments for myeloproliferative neoplasms, for up to $1.5 billion. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Calytrix Bio do?

Calytrix Bio is a privately held biotechnology company developing precision, disease-modifying therapies for myeloproliferative neoplasms. Its initial focus is mCALR-driven essential thrombocythemia and myelofibrosis. It is privately held, operating in Biotechnology, and is based in Massachusetts.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.